A Phase 1 interventional study of UPB-101 and Placebo in Asthma, sponsored by Upstream Bio Inc.. Completed at 4 sites in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-01-03.
Sponsored by Upstream Bio Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.
Among the 558 studies in Asthma with a site in United Kingdom, this one is the 313th largest by enrollment of the 427 interventional ones that give a count, is one of 26 that started in 2022, is one of 81 in phase 1, and was the 460th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Liverpool Heart and Chest Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–110
GlaxoSmithKline · Sites in United Kingdom, United States, Argentina and 1 more country
Ages 18+
University of Leeds · Sites in United Kingdom
Ages 18–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
558 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 132 · Phase 3 83 · Phase 4 50
First in 1991; this study’s year is marked. 26 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 69 across the 427 interventional studies, 149 across the 131 observational. Of the 445 that completed or were terminated, 155 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
320 of 558 have an industry lead sponsor. The 10 most frequent:
Upstream Bio Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Upstream Bio Inc. has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
23 of the studies in Asthma with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT07833826University of NottinghamN-WATCH: Nottingham Wheeze Assessment in Tidal Children | 2026-12-31 |
| NCT07488897RIGImmune Inc.RIG 101 Trial in Healthy Adults and Adults With Asthma | 2027-02 |
Add all 23 to your calendar (.ics) → With an account.
Among the 558 studies in Asthma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goals of this clinical study were to assess the safety, tolerability, blood levels, and disease impact of UPB-101 when given to adults with mild asthma. Eligible participant were consecutively assigned to 1 of 3 to 5 planned treatment groups. Each treatment group consisted of 8 individuals, six of whom will received active drug (UPB-101) and 2 who received placebo. Neither the study doctors nor the participants knew which participants were assigned to active study drug and which were assigned to placebo. The study was performed at 4 experienced research sites in the United Kingdom.
This was a two-part phase 1b, multi-center randomized, double-blind (Investigator and Subject blinded; Sponsor unblinded), placebo-controlled, multiple ascending-dose study to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of UPB-101 administered subcutaneously (SC) to adult subjects with asthma.
The study consists of Part A and Part B. Part A included 3 cohorts with pre-set dosing regimens. Part B (optional) included up to 2 additional cohorts whose doses and dosing intervals decided based upon the safety, PK, and PD results from Part A (i.e., an adaptive design), as applicable. The regimens selected for Part B did not exceed the exposures (i.e., doses and/or dosing intervals) included in Part A. Eight subjects were randomized per cohort (6 active, 2 placebo). Thus, a total of 32 subjects were enrolled in the study with 24 subjects in Part A and 8 in Part B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
UPB-101 Cohort 1
Drug: UPB-101 · Drug: Placebo
UPB-101 Cohort 2
Drug: UPB-101 · Drug: Placebo
UPB-101 Cohort 3
Drug: UPB-101 · Drug: Placebo
UPB-101 Cohort 4
Drug: UPB-101 · Drug: Placebo
Subcutaneous injection
Also known as: Formerly ASP7266
Subcutaneous injection
Also known as: 0.9% saline solution
Number of Treatment-emergent Adverse Events and Serious Adverse Events
Overall Summary of Treatment-emergent Adverse Events (TEAEs) and Adverse Events (AEs) up to Week 24 (Safety Population)
Time frame: Baseline through 24 weeks
Incidence of Anti-drug Antibodies
Blood samples were analyzed for the presence of ADAs using validated assays. Low titer ADA responses were detected toward the end of the concentration vs time profile. There was no evident effect of ADAs on drug exposure and no immune-related adverse events
Time frame: Baseline through Week 32
Maximum Observed Concentration of UPB-101
Blood samples were collected and analyzed using a validated assay to determine the Cmax (ug/mL) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.
Time frame: First Dose = Day 1. Last Dose = Baseline through 32 weeks.
Time to Maximum Observed Concentration of UPB-101
Blood samples were collected and analyzed using a validated assay to determine the Tmax (days) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.
Time frame: Baseline through 32 weeks
Area Under the Concentration-time Curve Under One Dosing Interval of UPB-101
Blood samples were collected and analyzed using a validated assay to determine the AUClast (d.ug/mL) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.
Time frame: Baseline through 32 weeks
The study was conducted in 4 sites in the United Kingdom (UK).
| Milestone | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 8 |
| Completed | 6 | 6 | 6 | 6 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Overall Summary of Treatment-emergent Adverse Events (TEAEs) and Adverse Events (AEs) up to Week 24 (Safety Population)
| adverse events | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo |
|---|---|---|---|---|---|
| any TEAEs | 19 | 17 | 12 | 9 | 25 |
| SAEs | 0 | 0 | 0 | 0 | 0 |
Blood samples were analyzed for the presence of ADAs using validated assays. Low titer ADA responses were detected toward the end of the concentration vs time profile. There was no evident effect of ADAs on drug exposure and no immune-related adverse events
| Participants | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo |
|---|---|---|---|---|---|
| Incidence of Anti-drug Antibodies | 4 | 5 | 1 | 2 | 0 |
Blood samples were collected and analyzed using a validated assay to determine the Cmax (ug/mL) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.
| ug/mL | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 |
|---|---|---|---|---|
| Cmax after first dose | 8.82 ± 2.25 | 21.8 ± 3.78 | 32.4 ± 6.23 | 1.85 ± 0.602 |
| Cmax after last dose | 16.3 ± 5.03 | 41.8 ± 5.69 | 33.8 ± 8.39 | — |
Blood samples were collected and analyzed using a validated assay to determine the Tmax (days) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.
| days | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 |
|---|---|---|---|---|
| Tmax after first dose | 6.98 (2.92 to 14.0) | 5.95 (2.77 to 13.9) | 6.93 (5.93 to 6.98) | 9.94 (2.90 to 20.9) |
| Tmax after last dose | 5.00 (2.99 to 7.04) | 3.94 (2.90 to 6.91) | 4.98 (2.91 to 13.9) | — |
Blood samples were collected and analyzed using a validated assay to determine the AUClast (d.ug/mL) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.
| day*μg/mL | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 |
|---|---|---|---|---|
| AUClast after the first dose | 187 ± 40.8 | 449 ± 101 | 1220 ± 236 | 73.4 ± 26.6 |
| AUClast after the last dose | 613 ± 115 | 1740 ± 496 | 1420 ± 453 | — |
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Substance 1 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Active Substance 2 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Active Substance 3 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Active Substance 4 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Placebo | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Event | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/6 | 2/6 | 2/6 | 1/6 | 0/8 |
| RhinitisInfections and infestations | 1/6 | 2/6 | 0/6 | 0/6 | 3/8 |
| COVID-19Infections and infestations | 1/6 | 0/6 | 2/6 | 0/6 | 1/8 |
| Viral upper respiratory tract infectionInfections and infestations | 0/6 | 0/6 | 2/6 | 0/6 | 0/8 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 2/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 1/6 | 0/6 | 2/8 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 2/8 |
| Ligament sprainInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 2/8 |
| Ear infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| HordeolumInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| Age, Continuous(years) | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 35.7 ± 10.31 | 37.7 ± 8.82 | 32.7 ± 9.54 | 48.0 ± 5.25 | 37.0 ± 11.41 | 38.1 ± 10.22 |
| Sex: Female, Male(Participants) | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 4 | 2 | 2 | 3 | 16 |
| Male | 1 | 2 | 4 | 4 | 5 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 1 | 2 |
| Not Hispanic or Latino | 5 | 6 | 6 | 6 | 7 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 3 | 0 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 | 2 |
| White | 4 | 4 | 2 | 6 | 7 | 23 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| United Kingdom | 6 | 6 | 6 | 6 | 8 | 32 |
| BMI at Screening (kg/m2)(kg/m^2) | Active Substance 1 | Active Substance 2 | Active Substance 3 | Active Substance 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 26.57 ± 3.025 | 25.18 ± 2.074 | 25.22 ± 2.848 | 27.65 ± 2.518 | 25.56 ± 3.110 | 26.01 ± 2.784 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Aug 2023, 13 months.
Results were first posted in Jan 2025, 1 year 4 months after primary completion.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 13 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verekitug
Upstream Bio Inc.